Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cipla employee settles...

    Cipla employee settles case with SEBI, pays Rs 3 lakh

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-25T09:25:07+05:30  |  Updated On 25 Sept 2019 9:25 AM IST
    Cipla employee settles case with SEBI, pays Rs 3 lakh

    SEBI, during its preliminary examination, observed that there was a delay on the part of Pathak in making a disclosure to the company under SEBI's PIT (Prohibition of Insider Trading) norms in respect of change in her shareholding in the scrip of Cipla.


    New Delhi: Markets regulator Securities and Exchange Board of India (SEBI), has settled a case with an employee of Cipla for alleged delay in making requisite disclosures regarding her shareholding in the company.


    The watchdog has settled the matter with Ranjana Pathak, a designated employee of the company, on payment of Rs 3 lakh towards settlement charges, SEBI said in a settlement order.


    The regulator, during its preliminary examination, observed that there was a delay on the part of Pathak in making a disclosure to the company under SEBI's PIT (Prohibition of Insider Trading) norms in respect of change in her shareholding in the scrip of Cipla.


    Before proceeding further and initiating proceedings, SEBI issued a settlement notice to Pathak in June, intimating thereby that the proceedings may be settled and disposed of upon filing of a settlement application. Following this, Pathak approached SEBI to settle the case.


    "The proposed proceedings that could have been initiated for the defaults...are settled qua the applicant (Pathak)," Sebi said.


    SEBI would not initiate any enforcement action against the applicant for the defaults.


    The regulator noted that it would have the right to take enforcement actions if it finds that any representation made by the applicant is subsequently discovered to be untrue.


    Read Also: Cipla arm, Novartis enter agreement for Ultibro Breezhaler to treat COPD

    Ciplacipla employeeinsider tradingpharmapharma companypharma newspharma news indiaPITRanjana PathakSEBISecurities and Exchange Board of India
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok